Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 5/20 | 0.34 |
| ▸ | MMP3 | P08254 | 5/20 | 0.34 |
| ▸ | MMP7 | P09237 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264978 | 0.87 | F10 (0.40) | SCN10A | |
| SCHEMBL6498866 | 0.82 | HCAR3 (0.33) | SCN10AMMP1MMP3MMP7 | |
| SCHEMBL6500557 | 0.81 | HCAR3 (0.38) | SCN10AMMP1MMP3MMP7TAAR1 | |
| SCHEMBL6245308 | 0.76 | SCN10A (0.39) | SCN10ATAAR1AAK1 | |
| SCHEMBL6499078 | 0.74 | HDAC6 (0.36) | MMP1MMP3MMP7ALDH1A1AAK1 | |
| Hydrochloric Acid SCHEMBL5858865 | 0.72 | TAAR1 (0.56) | MMP1MMP3MMP7ALDH1A1TAAR1 | |
| SCHEMBL6217633 | 0.70 | KDM4E (0.36) | MMP3MMP7ALDH1A1AAK1HDAC6 | |
| SCHEMBL6490467 | 0.69 | F10 (0.39) | SCN10A | |
| SCHEMBL4399656 | 0.69 | HSP90AA1 (0.45) | ALDH1A1NPC1RAB9AHDAC6 | |
| SCHEMBL6268953 | 0.68 | HCAR3 (0.40) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | SCN10A 4810/4885MMP1 3734/4885MMP3 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.